NK can kill tumor cells directly (releasing soluble granules, expressing apoptosis-inducing ligands, ADCC function) or indirectly (secreting a variety of cytokines, chemotactic molecules and growth factors to activate other immune cells). , which is expected to treat a variety of hematological tumors and solid tumors.

iPSC-NK products have the advantages of large batch output, stable quality, superior tumor killing performance, resistance to cryopreservation and recovery, and easy multi-element gene modification.

Nuwacell’s “NCR300” has entered the clinical trial stage for the treatment of MDS and the prevention of AML relapse following allo-HSCT. It is the first iNK cell therapy product approved for clinical trials in China. Moving forward, Nuwacell will continue to advance the development of iNK cell therapies targeting various indications.